A step-wise, deterministic and fatal mouse model of myeloid neoplasm with spontaneous acquisition of patient-relevant RTK–RAS mutations
Leukaemia arises through the stepwise transformation of healthy haematopoietic cells, yet the asymptomatic premalignant phase and its progression to overt disease remain poorly understood. To model this process, we engineered a patient-derived CEBPA mutation into Hoxb8-FL multipotent murine progenitors and transplanted them into syngeneic mice, capturing a clinically silent premalignant stage. All recipients developed overt disease after ~12 months with 100% penetrance and all acquired secondary RTK-RAS mutations, often with identical amino acid changes to those in patients. Single-cell transcriptomics and phenotypic profiling showed that premalignant mutant cells adopt a plasmacytoid dendritic progenitor-like state in vitro which generates both myeloid and B-lymphoid lineages during premalignancy in vivo, with individual tumours restricted to one lineage. The specificity for RTK-RAS mutations coupled with ongoing differentiation, reflects clinically relevant biological contexts thus providing a tractable model of myeloid neoplasm for mechanistic studies and drug discovery.
Authors
- Katherine Sturgess (ORCID: https://orcid.org/0000-0002-6969-4747)
- George Giotopoulos (ORCID: https://orcid.org/0000-0003-1390-6592)
- Berthold Göttgens (ORCID: https://orcid.org/0000-0001-6302-5705)
- M. S. Vijayabaskar
- Brian J.P. Huntly (ORCID: https://orcid.org/0000-0003-0312-161X)
- Marija Zarocsinceva (ORCID: https://orcid.org/0000-0001-6015-3656)
- Nicola K. Wilson (ORCID: https://orcid.org/0000-0003-0865-7333)
- David J. Adams (ORCID: https://orcid.org/0000-0001-9490-0306)
- Fernando J. Calero-Nieto
- M. Saeed Qureshi
- Blaise Musabe
- Ryan Asby
- Sarah J. Kinston
Institutions
- Wellcome/MRC Cambridge Stem Cell Institute (GB)
- University of Cambridge (GB)
- Wellcome Sanger Institute (GB)
Publication Details
- Journal
- Oncogene
- Published
- 2026-09-04
- DOI
- https://doi.org/10.1038/s41388-026-03964-w
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- UK Research and Innovation
- Cancer Research UK
- National Institute for Health and Care Research
- Department of Health and Social Care
- Blood Cancer UK
- Medical Research Council
- Cambridge Institute for Medical Research, University of Cambridge
- NIHR Cambridge Biomedical Research Centre
- Cancer Research UK Cambridge Institute, University of Cambridge